EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Targeted Mass Azithromycin Distribution for Trachoma: A Community-Randomized Trial (TANA II)

Hamidah Mahmud, Berhan A Haile, Zerihun Tadesse, Sintayehu Gebresillasie, Ayalew Shiferaw, Mulat Zerihun, Zijun Liu, E Kelly Callahan, Sun Y Cotter, Nicole E Varnado, Catherine E Oldenburg, Travis C Porco und 2 weitere

Clinical Infectious Diseases · 2023

DOI: 10.1093/cid/ciad211 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Hamidah Mahmud und 13 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of California, San Francisco, California, USA. Hauptthemen laut MEDLINE: Azithromycin, Trachoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NEI NIH HHS, National Eye Institute, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Current guidelines recommend annual community-wide mass administration of azithromycin for trachoma. Targeting treatments to those most likely to be infected could reduce the amount of unnecessary antibiotics distributed.

Methods

In a cluster-randomized trial conducted from 1 November 2010 through 8 November 2013, 48 Ethiopian communities previously treated with annual mass azithromycin distributions for trachoma were randomized in equal numbers to (1) annual azithromycin distributions targeted to children aged 0–5 years, (2) annual azithromycin distributions targeted to households with a child aged 0–5 years found to have clinically active trachoma, (3) continued annual mass azithromycin distributions to the entire community, or (4) cessation of treatment. The primary outcome was the community prevalence of ocular chlamydia infection among children aged 0–9 years at month 36. Laboratory personnel were masked to treatment allocation.

Results

The prevalence of ocular chlamydia infection among children aged 0–9 years increased from 4.3% (95% confidence interval [CI], .9%–8.6%) at baseline to 8.7% (95% CI, 4.2%–13.9%) at month 36 in the age-targeted arm, and from 2.8% (95% CI, .8%–5.3%) at baseline to 6.3% (95% CI, 2.9%–10.6%) at month 36 in the household-targeted arm. After adjusting for baseline chlamydia prevalence, the 36-month prevalence of ocular chlamydia was 2.4 percentage points greater in the age-targeted group (95% CI, −4.8% to 9.6%; P = .50; prespecified primary analysis). No adverse events were reported.

Conclusions

Targeting azithromycin treatment to preschool children was no different than targeting azithromycin to households with a child with clinically active trachoma. Neither approach reduced ocular chlamydia over the 3-year study. Clinical Trials Registration NCT01202331.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AzithromycinTrachomaChild, PreschoolHumansInfantAnti-Bacterial AgentsChlamydia trachomatisMass Drug AdministrationPrevalenceInfant, Newborn

Stichwörter der Autor:innen

chlamydiaclinical trialmass drug administrationtrachoma

Substanzen

Anti-Bacterial AgentsAzithromycin

Autor:innen und Institutionen

  • School of Medicine, University of California, San Francisco, California, USA.
  • Francis I. Proctor Foundation, University of California, San Francisco, California, USA.
  • The Carter Center Ethiopia, Addis Ababa, Ethiopia.
  • Department of Ophthalmology, University of California, San Francisco, California, USA.
  • Department of Epidemiology & Biostatistics, University of California, San Francisco, California, USA.

Förderung

  • NEI NIH HHS
  • National Eye Institute
  • National Institutes of Health
  • Research to Prevent Blindness
  • International Trachoma Initiative
  • Carter Center
  • Amhara Regional Health Bureau

Zitieren

APA

Mahmud, H., Haile, B. A., Tadesse, Z., Gebresillasie, S., Shiferaw, A., Zerihun, M., Liu, Z., Callahan, E. K., Cotter, S. Y., Varnado, N. E., Oldenburg, C. E., Porco, T. C., Lietman, T. M., & Keenan, J. D. (2023). Targeted Mass Azithromycin Distribution for Trachoma: A Community-Randomized Trial (TANA II). Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad211

Vancouver

Mahmud H, Haile BA, Tadesse Z, Gebresillasie S, Shiferaw A, Zerihun M, et al. Targeted Mass Azithromycin Distribution for Trachoma: A Community-Randomized Trial (TANA II). Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciad211

BibTeX
@article{Mahmud2023,
  author = {Mahmud, Hamidah and Haile, Berhan A and Tadesse, Zerihun and Gebresillasie, Sintayehu and Shiferaw, Ayalew and Zerihun, Mulat and Liu, Zijun and Callahan, E Kelly and Cotter, Sun Y and Varnado, Nicole E and Oldenburg, Catherine E and Porco, Travis C and Lietman, Thomas M and Keenan, Jeremy D},
  title = {Targeted Mass Azithromycin Distribution for Trachoma: A Community-Randomized Trial (TANA II)},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  doi = {10.1093/cid/ciad211}
}
Kostenlos starten →